It was suggested that cathepsin B (CTSB) released from the lysosomes after RD‐N treatment triggered apoptosis in prostate cancer (PCa) cells,1 but the underlying molecular mechanisms responsible for the effects remained unknown. Here, CTSB is linked to prostate carcinoma.